"If I'm looking from this
purely from the payer perspective, that might potentially create some
confusion…Some insurers will cover more testing than others. Where they don't
clarify the interval, that's an issue for the payer, the provider and the
patient."
— Richard Hughes IV, a principal at Avalere Health, spoke with
AIS's RADAR on Drug Benefits about the U.S. Preventive Services Task Force
(USPSTF) expanded hepatitis C screening recommendations, and where payers may
run into some confusion, as the USPSTF did not outline how often people should
be tested.
No comments:
Post a Comment